PMID- 28294917
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20191120
IS  - 0022-9040 (Print)
IS  - 0022-9040 (Linking)
VI  - 55
IP  - 8
DP  - 2015 Aug
TI  - [Effects of Meldonia in Early Postmyocardial Infarction Period].
PG  - 35-42
AB  - The aim of PMICS (Postmyocardial Infarction Cardiosclerosis) patients therapy 
      within the dispensary supervision is CCI (Chronic Cardio Insufficiency) 
      progression prevention, life quality improvement, hospitalization number decrease 
      and life prognosis improvement. Despite the developed approaches to the given 
      patients treatment, CCI progression prevention, the main disease treatment 
      ensuring and prognosis assessment are not always as much as possible effective. 
      The search of methods improving the given patients prognosis is highly actual. 
      THE AIM: To evaluate the meldonium clinical effectiveness in the early 
      postmyocardial infarction period. MATERIALS AND METHODS: 67 patients were 
      included in investigation, their age ranged from 40 to 70. They survived 
      myocardial infarction (MI) and were discharged for further ambulatory 
      supervision. The patients were randomized into two groups: the first one 
      consisting of 32 patients got basic therapy for ischemic heart disease (IHD). The 
      second group consisting of 35 patients besides basic therapy got mildronate 
      during 12 weeks. RESULTS: meldonium included in standard ischemic heart disease 
      therapy in early postmyocardial infarction cardiosclerosis reduces the rate of 
      angina pectoris attacks (p=0,001), decreased the number of epiventricular 
      extrasystoles (p=0,002) and the number of paroxysmal rhythm disturbances 
      (p=0,001), decreased arterial blood pressure (middle SAP and DAP) p=0,001, 
      improves life quality and lowered the level of anxiety (p=0,001). CONCLUSION: The 
      results received are likely to depend on the use of energetically advantageous 
      pyruvate in glycolytic cycle due to restoration of equilibrium in processes of 
      oxygen supply and its consumption, prevention of ATA (adenozine tryphosphoric 
      acid) transport disturbances, elimination of toxic metabolic products 
      accumulation. No side effects were registered during the course of mildronate 
      treatment.
FAU - Nechaeva, G I
AU  - Nechaeva GI
AD  - 1Omsk State Medical University, Omsk, Russia; 2Clinical Cardiological Dispensary, 
      Omsk, Russia2.
FAU - Zheltikova, E N
AU  - Zheltikova EN
AD  - 1Omsk State Medical University, Omsk, Russia; 2Clinical Cardiological Dispensary, 
      Omsk, Russia2.
LA  - rus
PT  - English Abstract
PT  - Journal Article
PL  - Russia (Federation)
TA  - Kardiologiia
JT  - Kardiologiia
JID - 0376351
EDAT- 2015/08/01 00:00
MHDA- 2015/08/01 00:01
CRDT- 2017/03/16 06:00
PHST- 2017/03/16 06:00 [entrez]
PHST- 2015/08/01 00:00 [pubmed]
PHST- 2015/08/01 00:01 [medline]
PST - ppublish
SO  - Kardiologiia. 2015 Aug;55(8):35-42.